Dennis Walsh Net Worth

The estimated Net Worth of Dennis Leo Walsh is at least $501 Thousand dollars as of 10 May 2023. Mr. Walsh owns over 11,000 units of Deciphera Pharmaceuticals Inc stock worth over $281,490 and over the last 7 years he sold DCPH stock worth over $0. In addition, he makes $219,964 as Independent Director at Deciphera Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Walsh DCPH stock SEC Form 4 insiders trading

Dennis has made over 1 trades of the Deciphera Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 11,000 units of DCPH stock worth $152,460 on 10 May 2023.

The largest trade he's ever made was buying 11,000 units of Deciphera Pharmaceuticals Inc stock on 10 May 2023 worth over $152,460. On average, Dennis trades about 917 units every 0 days since 2018. As of 10 May 2023 he still owns at least 11,000 units of Deciphera Pharmaceuticals Inc stock.

You can see the complete history of Mr. Walsh stock trades at the bottom of the page.

Dennis Walsh biography

Dennis Leo Walsh serves as Independent Director of the Company. Mr. Walsh is currently Senior Vice President and Chief Financial Officer of Americo Life, Inc., a privately owned life insurance company, a role he has held since October 2018. Prior to Americo, Mr. Walsh was a partner with Walsh Washburn, LLC, a tax and finance consulting firm, which he co-founded in 2003. Prior to founding Walsh Washburn, LLC, Mr. Walsh was the controller and tax director for six years for Americo Life, Inc. Mr. Walsh began his career with Touche Ross & Company, where he served in the tax department for ten years. Mr. Walsh holds a Masters in Accounting from the University of Missouri, Kansas City as well as a BSBA in Accounting from Rockhurst University, and is a Certified Public Accountant.

What is the salary of Dennis Walsh?

As the Independent Director of Deciphera Pharmaceuticals Inc, the total compensation of Dennis Walsh at Deciphera Pharmaceuticals Inc is $219,964. There are 18 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.

How old is Dennis Walsh?

Dennis Walsh is 52, he's been the Independent Director of Deciphera Pharmaceuticals Inc since 2015. There are 14 older and 6 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.

What's Dennis Walsh's mailing address?

Dennis's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.

What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

Complete history of Mr. Walsh stock trades at Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Steven Hoerter,
  President, Chief Executive Officer, Director
• Michael Taylor,
  Director
• Matthew Sherman,
  Executive Vice President, Chief Medical Officer
• Thomas Kelly,
  Chief Financial Officer, Executive Vice President, Treasurer
• Steven L. Hoerter,
  Pres, CEO & Director
• Daniel Flynn,
  Founder, Executive Vice President, Chief Scientific Officer
• Dr. Matthew L. Sherman,
  Exec. VP & Chief Medical Officer
• Ron Squarer,
  Independent Director
• Frank Friedman,
  Independent Director
• Thomas Patrick Kelly J.D.,
  Exec. VP, CFO & Treasurer
• Dr. Matthew L. Sherman M.D.,
  Exec. VP & Chief Medical Officer
• Dr. Daniel L. Flynn,
  Exec. VP, Chief Scientific Officer & Founder
• Daniel C. Martin,
  Sr. VP & Chief Commercial Officer
• Dr. Stephen B. Ruddy Ph.D.,
  Sr. VP & Chief Technical Officer
• Susan Kelley,
  Independent Director
• James Bristol,
  Independent Chairman of the Board
• Edward Benz,
  Independent Director
• Patricia Allen,
  Independent Director
• Dennis Walsh,
  Independent Director
• John Martin,
  Independent Director
• Melissa Forst,
  IR Contact Officer
• Lisa Amaya Price,
  Sr. VP & Chief HR Officer
• Jennifer Larson,
  Sr. VP of Fin. & Investor Relations
• Margarida Duarte,
  Sr. VP & Head of International
• Jama Pitman,
  Sr. VP of Regulatory, Quality & Portfolio Management
• Jeffrey M. Held J.D.,
  Sr. VP & Gen. Counsel
• Jennifer Robinson,
  VP of Investor Relations
• Dashyant Dhanak,
  EVP & Chief Scientific Officer
• Leaf Venture Management Iii...,
  
• Liam Ratcliffe,
  Director
• Associates Llc Brightstar,
  10% owner
• Christopher John Morl,
  Chief Business Officer
• Michael Jay Ross,
  Director
• Oliver Rosen,
  Chief Medical Officer
• Stephen B. Ruddy,
  Chief Technical Officer
• Daniel C. Martin,
  Chief Commercial Officer
• Jama Pitman,
  SVP, Chief Development Officer